Home › Alnylam trial confirms continued effectiveness of RNAi drugs
 

Keywords :   


Alnylam trial confirms continued effectiveness of RNAi drugs

2015-04-21 13:50:02| Biotech - Topix.net

Trial results released today suggest the lead drug by Alnylam Pharmaceuticals for a rare neurodegenerative disease continues to stop nerve damage after a year, confirming earlier results. The trial is the longest one yet to measure the neuropathic effects of the drug by Alnylam , called Patisiran.

Tags: trial continued drugs effectiveness

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05Water investors have withdrawn billions, says research
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05IT Cosmetics and Kenvue Launch New Products
19.05Virgin Trains targets West Coast in return to rail
19.05Cashing In On The Stache
More »